Compare · TMO vs VAPE
TMO vs VAPE
Side-by-side comparison of Thermo Fisher Scientific Inc (TMO) and CEA Industries Inc. (VAPE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both TMO and VAPE operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO carries a market cap of $175.70B.
- Over the past year, TMO is up 15.7% and VAPE is up 146.2% - VAPE leads by 130.4 points.
- TMO has hit the wire 17 times in the past 4 weeks while VAPE has been quiet.
- TMO has more recent analyst coverage (25 ratings vs 0 for VAPE).
- Company
- Thermo Fisher Scientific Inc
- CEA Industries Inc.
- Price
- $472.92+0.04%
- $17.60+0.54%
- Market cap
- $175.70B
- -
- 1M return
- -0.32%
- +69.39%
- 1Y return
- +15.74%
- +146.15%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 17
- 0
- Recent ratings
- 25
- 0
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest TMO
- Thermo Fisher downgraded by HSBC Securities with a new price target
- Wolfe Research resumed coverage on Thermo Fisher with a new price target
- SEC Form SD filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Weisler Dion J covered exercise/tax liability with 80 shares and was granted 499 shares, increasing direct ownership by 8% to 5,446 units (SEC Form 4)
- Director Sperling Scott M was granted 499 shares, increasing direct ownership by 0.72% to 69,479 units (SEC Form 4)
- Director Spar Debora L was granted 499 shares, increasing direct ownership by 24% to 2,610 units (SEC Form 4)
- Director Lynch Karen S was granted 499 shares, increasing direct ownership by 76% to 1,159 units (SEC Form 4)
- Director Keith R. Alexandra was granted 499 shares, increasing direct ownership by 24% to 2,602 units (SEC Form 4)
Latest VAPE
- Amendment: SEC Form 4 filed by Director Shipley James Randall
- Amendment: SEC Form 4 filed by Director Mariathasan Marion
- Amendment: SEC Form 4 filed by Director Tarallo Matthew
- Director Tarallo Matthew was granted 1,529 shares, increasing direct ownership by 100% to 3,058 units (SEC Form 4)
- CEA Industries Closes $500 Million Private Placement to Advance Its BNB Treasury Strategy; Common Stock Ticker to Become "BNC"
- CEA Industries Inc. Announces Ticker Symbol Change to "BNC" for Common Stock and "BNCWW" for Warrants
- CEA Industries Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Nano Labs Invests in BNB Strategic Reserve Company CEA INDUSTRIES INC. to Further Strengthen BNB Reserve Strategy
- SEC Form 4 filed by Director Etten Nicholas J.
- SEC Form 4 filed by Director Tarallo Matthew